OBJECTIVES: To assess the clinical effectiveness and economic consequences of Betaloc ZOC (metoprolol succinate) or carvedilol in treatment of cardiac insufficiency and hypertension from public payer perspective in Poland. METHODS: Results of a systematic review of published clinical trials selected in accordance with EBM criteria were used to assess effectiveness and safety of the drugs in cardiac insufficiency and hypertension treatment. The economic consequences for public payer for therapy of individual patient in case of carvedilol replacement by Betaloc ZOC were calculated. Costs of treatment depend on pharmacotherapy as well as risk of adverse events and probability of hospital stay due to the drugs use. Sensitivity analyses were performed for a range of costs of Betaloc ZOC or carvedilol generics available in Poland. RESULTS: Systematic review revealed no “head to head” comparison between metoprolol succinate and carvedilol; indirect comparisons showed superiority of Betaloc ZOC in cardiac insufficiency as well as hypertension treatment. Annual treatment costs from public payer perspective in case of Betaloc ZOC use were much lower than in case of carvedilol in cardiac insufficiency (difference: 214.8 (51.1E) – 2696.8PLN (642E) per patient). Carvedilol was dominated by Betaloc ZOC in hypertension treatment: Betaloc ZOC has higher clinical effectiveness and generates savings (lower risk of adverse events or hospitalization) compared to carvedilol: 445.17 (106E) – 4270.5PLN (1016.8E) in case of annual treatment of one patient. Sensitivity analysis showed than in most scenarios Betaloc was cheaper from public payer perspective than carvedilol. CONCLUSION: Betaloc ZOC use in place of carvedilol lead to significant savings for public payer in Poland in cardiac insufficiency and hypertension treatment.